Netarsudil Ophthalmic Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Netarsudil Ophthalmic comprises 43 peer-reviewed publications across 15 journals, 7 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Glaucoma, Open-Angle, Fuchs' Endothelial Dystrophy, and Vitreoretinopathy, Proliferative. Most recent publication: Prospective Assessment of Adjuvant Netarsudil Use in Patients Undergoing Descemet Stripping Only., Cornea, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
    Price MO, Price FW · Am J Ophthalmol · 2021
    PubMed: PMID 33737034 · NCT04051463 · Fuchs' Endothelial Dystrophy
  2. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Zaman F, Gieser SC, Schwartz GF, et al. · Curr Med Res Opin · 2021
    PubMed: PMID 33733980 · NCT03808688 · Glaucoma, Open-Angle
  3. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    Price MO, Feng MT, Price FW, et al. · Am J Ophthalmol · 2021
    PubMed: PMID 33045216 · NCT03248037 · Fuchs' Endothelial Dystrophy
  4. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
    Peace JH, McKee HJ, Kopczynski CC, et al. · Ophthalmol Ther · 2021
    PubMed: PMID 33244711 · NCT02874846 · Glaucoma, Open-Angle
  5. Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
    Lindstrom RL, Lewis AE, Holland EJ, et al. · J Ocul Pharmacol Ther · 2022
    PubMed: PMID 36327101 · NCT04498169 (Fuchs) · Fuchs' Endothelial Dystrophy
  6. Prospective Assessment of Adjuvant Netarsudil Use in Patients Undergoing Descemet Stripping Only.
    Bal S, Pineda R, Davies E, et al. · Cornea · 2025
    PubMed: PMID 38780446 · NCT04752020 · Fuchs' Endothelial Dystrophy
  7. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Araie M, Sugiyama K, Aso K, et al. · Adv Ther · 2021
    PubMed: PMID 33629227 · NCT03844945 · Glaucoma, Open-Angle
  8. Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
    Araie M, Sugiyama K, Aso K, et al. · Adv Ther · 2023
    PubMed: PMID 37603205 · NCT04620135 · Glaucoma, Open-Angle

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02558400Glaucoma, Open-AngleIntraocular Pressure (IOP)
Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)
AR-13324 Ophthalmic Solution 0.02%23.45 mmHg (±3.510 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.78 mmHg (±4.219 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%18.66 mmHg (±4.189 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.96 mmHg (±4.262 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.25 mmHg (±3.814 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%24.81 mmHg (±3.335 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%19.04 mmHg (±4.537 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%19.06 mmHg (±4.593 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.30 mmHg (±3.769 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%22.63 mmHg (±3.674 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.92 mmHg (±4.168 Standard Deviation)
AR-13324 Ophthalmic Solution 0.02%17.54 mmHg (±3.855 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.06 mmHg (±3.250 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%16.97 mmHg (±3.240 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.53 mmHg (±3.280 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%16.88 mmHg (±3.139 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.74 mmHg (±3.467 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%16.67 mmHg (±3.115 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.36 mmHg (±3.548 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%23.43 mmHg (±3.385 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.11 mmHg (±3.236 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%24.59 mmHg (±2.914 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.58 mmHg (±3.465 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%23.43 mmHg (±3.370 Standard Deviation)
PG324 Ophthalmic Solution16.04 mmHg (±3.268 Standard Deviation)
PG324 Ophthalmic Solution23.72 mmHg (±3.587 Standard Deviation)
PG324 Ophthalmic Solution22.59 mmHg (±3.610 Standard Deviation)
PG324 Ophthalmic Solution15.68 mmHg (±3.532 Standard Deviation)
PG324 Ophthalmic Solution14.93 mmHg (±3.417 Standard Deviation)
PG324 Ophthalmic Solution14.83 mmHg (±2.978 Standard Deviation)
PG324 Ophthalmic Solution24.84 mmHg (±3.316 Standard Deviation)
PG324 Ophthalmic Solution15.39 mmHg (±3.175 Standard Deviation)
PG324 Ophthalmic Solution15.43 mmHg (±3.065 Standard Deviation)
PG324 Ophthalmic Solution16.37 mmHg (±3.377 Standard Deviation)
PG324 Ophthalmic Solution15.41 mmHg (±3.038 Standard Deviation)
PG324 Ophthalmic Solution15.49 mmHg (±3.126 Standard Deviation)
NCT02674854Glaucoma, Open-AngleIntraocular Pressure (IOP)
3 months
Latanoprost Ophthalmic Solution 0.005%22.59 mmHg (±3.451 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.09 mmHg (±3.271 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.98 mmHg (±3.400 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.48 mmHg (±3.366 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%18.10 mmHg (±3.375 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.14 mmHg (±3.044 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.61 mmHg (±3.264 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%23.23 mmHg (±3.339 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.08 mmHg (±3.283 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%24.75 mmHg (±3.240 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.93 mmHg (±3.586 Standard Deviation)
Latanoprost Ophthalmic Solution 0.005%17.35 mmHg (±3.224 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%23.40 mmHg (±3.538 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%17.95 mmHg (±3.776 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%17.99 mmHg (±3.909 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%24.66 mmHg (±3.148 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%19.72 mmHg (±4.419 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%22.76 mmHg (±3.558 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%19.35 mmHg (±4.279 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%18.30 mmHg (±3.846 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%19.52 mmHg (±4.273 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%17.53 mmHg (±3.772 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%17.94 mmHg (±3.627 Standard Deviation)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%18.40 mmHg (±3.810 Standard Deviation)
PG324 Ophthalmic Solution16.43 mmHg (±3.717 Standard Deviation)
PG324 Ophthalmic Solution23.33 mmHg (±3.399 Standard Deviation)
PG324 Ophthalmic Solution22.37 mmHg (±3.492 Standard Deviation)
PG324 Ophthalmic Solution16.06 mmHg (±3.370 Standard Deviation)
PG324 Ophthalmic Solution15.31 mmHg (±3.272 Standard Deviation)
PG324 Ophthalmic Solution15.16 mmHg (±3.032 Standard Deviation)
PG324 Ophthalmic Solution24.69 mmHg (±3.422 Standard Deviation)
PG324 Ophthalmic Solution15.54 mmHg (±3.533 Standard Deviation)
PG324 Ophthalmic Solution15.45 mmHg (±3.525 Standard Deviation)
PG324 Ophthalmic Solution16.45 mmHg (±3.572 Standard Deviation)
PG324 Ophthalmic Solution15.58 mmHg (±3.307 Standard Deviation)
PG324 Ophthalmic Solution15.52 mmHg (±3.210 Standard Deviation)
NCT03248037Fuchs' Endothelial DystrophyIntraocular Pressure
from date of randomization until the date of first documented intraocular pressure elevation exceeding defined threshold up to 9 months
Netarsudil11 Participants
Placebo18 Participants
NCT03284853Glaucoma, Open-AngleMean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
Day 90
GANFORT®15.19 mmHg
GANFORT®15.56 mmHg
GANFORT®15.25 mmHg
Netarsudil/Latanoprost 0.02%/0.005%15.64 mmHg
Netarsudil/Latanoprost 0.02%/0.005%15.61 mmHg
Netarsudil/Latanoprost 0.02%/0.005%15.39 mmHg
NCT03971357Fuchs' Endothelial DystrophyCorneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy
5 weeks
Netarsudil42 percentage of area stripped (±45 Standard Deviation)
Placebo43 percentage of area stripped (±49 Standard Deviation)
NCT04051463Fuchs' Endothelial DystrophyChange in Central Corneal Thickness
1 month
Netarsudil-23 microns
Placebo-2 microns
NCT04620135Glaucoma, Open-AngleIntraocular Pressure (IOP)
29 Days
Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle15.96 mmHg (±0.157 Standard Error)
Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%17.71 mmHg (±0.155 Standard Error)

Publications by year

1980–2025: 43 publications.

1980
1
1992
1
2002
1
2004
1
2006
1
2008
1
2009
2
2010
1
2012
1
2014
1
2015
1
2016
1
2017
2
2018
3
2019
6
2020
4
2021
10
2022
2
2023
2
2025
1

Publications by indication

Glaucoma, Open-Angle (22)

  • Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
    Adv Ther · 2023 · PMID 37603205 · NCT04620135
  • Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future.
    Cureus · 2023 · PMID 33391921 · NCT06865144
  • A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Curr Med Res Opin · 2021 · PMID 33733980 · NCT03808688
  • A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
    Ophthalmol Ther · 2021 · PMID 33244711 · NCT02874846
  • Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Adv Ther · 2021 · PMID 33629227 · NCT03844945

Fuchs' Endothelial Dystrophy (11)

  • Prospective Assessment of Adjuvant Netarsudil Use in Patients Undergoing Descemet Stripping Only.
    Cornea · 2025 · PMID 38780446 · NCT04752020
  • Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
    J Ocul Pharmacol Ther · 2022 · PMID 36327101 · NCT04498169
  • Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
    Am J Ophthalmol · 2021 · PMID 33737034 · NCT04051463
  • Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    Am J Ophthalmol · 2021 · PMID 33045216 · NCT03248037
  • Patient-Reported Visual Disability in Fuchs' Endothelial Corneal Dystrophy Measured by the Visual Function and Corneal Health Status Instrument.
    Ophthalmology · 2019 · PMID 30104038 · NCT03971357

Vitreoretinopathy, Proliferative (10)

  • Fasudil, a Clinically Used ROCK Inhibitor, Stabilizes Rod Photoreceptor Synapses after Retinal Detachment.
    Transl Vis Sci Technol · 2022 · PMID 28660097 · NCT05660447
  • Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
    J Glaucoma · 2021 · PMID 32826769 · NCT06033703
  • Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
    Cornea · 2021 · PMID 33369939 · NCT06033703
  • Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
    Cornea · 2021 · PMID 33758139 · NCT06033703
  • Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.
    Am J Ophthalmol · 2020 · PMID 32289295 · NCT06033703

Publications by journal

Trial-results highlights

Clinical trials have investigated Netarsudil Ophthalmic for open-angle glaucoma. In NCT02558400, the mean intraocular pressure (IOP) for the AR-13324 Ophthalmic Solution 0.02% arm ranged from 17.25 mmHg to 24.81 mmHg over 3 months. Similarly, in NCT02674854, the mean IOP for the Latanoprost Ophthalmic Solution 0.005% arm ranged from 17.09 mmHg to 22.59 mmHg over 3 months. In NCT03284853, the mean diurnal IOP on Day 90 was between 15.19 mmHg and 15.56 mmHg for the GANFORT® arm. For the Netarsudil/Latanoprost 0.02%/0.005% arm, the mean diurnal IOP on Day 90 ranged from 15.39 mmHg to 15.64 mmHg. Another study, NCT04620135, reported a least squares mean IOP of 15.96 mmHg for the Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle arm after 29 days, compared to 17.71 mmHg for the Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% arm.

In studies focusing on Fuchs' Endothelial Dystrophy, NCT03248037 reported that 11 participants in the Netarsudil arm experienced an intraocular pressure elevation exceeding a defined threshold up to 9 months, while 18 participants in the Placebo arm experienced this event. In NCT03971357, the mean corneal clearing after endothelial removal was 42 percentage of area stripped for the Netarsudil arm and 43 percentage of area stripped for the Placebo arm after 5 weeks. Additionally, NCT04051463 found a mean change in central corneal thickness of -23 microns for the Netarsudil arm and -2 microns for the Placebo arm after 1 month.

All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Netarsudil Ophthalmic publications (43)

2025 (1 paper)

  1. Prospective Assessment of Adjuvant Netarsudil Use in Patients Undergoing Descemet Stripping Only.
    Bal S, Pineda R, Davies E, et al. · Cornea · 2025 · Derived
    PubMed: PMID 38780446 · NCT04752020 · Fuchs' Endothelial Dystrophy

2023 (2 papers)

  1. Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
    Araie M, Sugiyama K, Aso K, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37603205 · NCT04620135 · Glaucoma, Open-Angle
  2. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future.
    Allison K, Patel D, Alabi O, et al. · Cureus · 2023 · Background
    PubMed: PMID 33391921 · NCT06865144 · Glaucoma, Open-Angle

2022 (2 papers)

  1. Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
    Lindstrom RL, Lewis AE, Holland EJ, et al. · J Ocul Pharmacol Ther · 2022 · Derived
    PubMed: PMID 36327101 · NCT04498169 (Fuchs) · Fuchs' Endothelial Dystrophy
  2. Fasudil, a Clinically Used ROCK Inhibitor, Stabilizes Rod Photoreceptor Synapses after Retinal Detachment.
    Townes-Anderson E, Wang J, Halász É, et al. · Transl Vis Sci Technol · 2022 · Background
    PubMed: PMID 28660097 · NCT05660447 · Vitreoretinopathy, Proliferative

2021 (10 papers)

  1. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
    Price MO, Price FW · Am J Ophthalmol · 2021 · Trial result
    PubMed: PMID 33737034 · NCT04051463 · Fuchs' Endothelial Dystrophy
  2. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Zaman F, Gieser SC, Schwartz GF, et al. · Curr Med Res Opin · 2021 · Derived
    PubMed: PMID 33733980 · NCT03808688 · Glaucoma, Open-Angle
  3. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    Price MO, Feng MT, Price FW, et al. · Am J Ophthalmol · 2021 · Derived
    PubMed: PMID 33045216 · NCT03248037 · Fuchs' Endothelial Dystrophy
  4. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
    Peace JH, McKee HJ, Kopczynski CC, et al. · Ophthalmol Ther · 2021 · Derived
    PubMed: PMID 33244711 · NCT02874846 · Glaucoma, Open-Angle
  5. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Araie M, Sugiyama K, Aso K, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 33629227 · NCT03844945 · Glaucoma, Open-Angle
  6. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    Sit AJ, Gupta D, Kazemi A, et al. · Am J Ophthalmol · 2021 · Background
    PubMed: PMID 33524367 · NCT07325240 · Glaucoma, Open-Angle
  7. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Singh IP, Fechtner RD, Myers JS, et al. · J Glaucoma · 2021 · Background
    PubMed: PMID 32826769 · NCT06033703 · Vitreoretinopathy, Proliferative
  8. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
    LoBue SA, Moustafa GA, Vu A, et al. · Cornea · 2021 · Background
    PubMed: PMID 33369939 · NCT06033703 · Vitreoretinopathy, Proliferative
  9. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
    Davies E, Jurkunas U, Pineda R, et al. · Cornea · 2021 · Background
    PubMed: PMID 33758139 · NCT06033703 · Vitreoretinopathy, Proliferative
  10. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
    Brubaker JW, Teymoorian S, Lewis RA, et al. · Ophthalmol Glaucoma · 2021 · Background
    PubMed: PMID 32768361 · NCT07325240 · Glaucoma, Open-Angle

2020 (4 papers)

  1. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
    Wisely CE, Sheng H, Heah T, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 31981106 · NCT02674854 · Glaucoma, Open-Angle
  2. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S, Bacharach J, Holland E, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 32166538 · NCT02558400 · Glaucoma, Open-Angle
  3. Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.
    Wisely CE, Liu KC, Gupta D, et al. · Am J Ophthalmol · 2020 · Background
    PubMed: PMID 32289295 · NCT06033703 · Vitreoretinopathy, Proliferative
  4. Improving outcomes in retinal detachment: the potential role of rho-kinase inhibitors.
    Halász É, Townes-Anderson E, Zarbin MA, et al. · Curr Opin Ophthalmol · 2020 · Background
    PubMed: PMID 32235252 · NCT05660447 · Vitreoretinopathy, Proliferative

2019 (6 papers)

  1. Patient-Reported Visual Disability in Fuchs' Endothelial Corneal Dystrophy Measured by the Visual Function and Corneal Health Status Instrument.
    Wacker K, Baratz KH, Bourne WM, et al. · Ophthalmology · 2019 · Background
    PubMed: PMID 30104038 · NCT03971357 · Fuchs' Endothelial Dystrophy
  2. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
    Lin CW, Sherman B, Moore LA, et al. · J Ocul Pharmacol Ther · 2019 · Background
    PubMed: PMID 28609185 · NCT06033703 · Vitreoretinopathy, Proliferative
  3. The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans.
    Kazemi A, McLaren JW, Kopczynski CC, et al. · J Ocul Pharmacol Ther · 2019 · Background
    PubMed: PMID 29469601 · NCT07325240 · Glaucoma, Open-Angle
  4. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
    Kahook MY, Serle JB, Mah FS, et al. · Am J Ophthalmol · 2019 · Background
    PubMed: PMID 30653957 · NCT06033703 · Vitreoretinopathy, Proliferative
  5. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
    Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. · Lancet · 2019 · Background
    PubMed: PMID 30862377 · NCT06865144 · Glaucoma, Open-Angle
  6. Reticular Epithelial Edema in Edematous Corneas Treated with Netarsudil.
    Fernandez MM · Ophthalmology · 2019 · Background
    PubMed: PMID 30318038 · NCT06033703 · Vitreoretinopathy, Proliferative

2018 (3 papers)

  1. Regenerative Therapy for Fuchs Endothelial Corneal Dystrophy.
    Soh YQ, Mehta JS · Cornea · 2018 · Background
    PubMed: PMID 29384808 · NCT03971357 · Fuchs' Endothelial Dystrophy
  2. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    Serle JB, Katz LJ, McLaurin E, et al. · Am J Ophthalmol · 2018 · Background
    PubMed: PMID 29199013 · NCT06033703 · Vitreoretinopathy, Proliferative
  3. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.
    Moloney G, Petsoglou C, Ball M, et al. · Cornea · 2018 · Background
    PubMed: PMID 28476048 · NCT03971357 · Fuchs' Endothelial Dystrophy

2017 (2 papers)

  1. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.
    Fini ME, Schwartz SG, Gao X, et al. · Prog Retin Eye Res · 2017 · Background
    PubMed: PMID 27666015 · NCT03248037 · Fuchs' Endothelial Dystrophy
  2. Treatment of Fuchs Endothelial Dystrophy by Descemet Stripping Without Endothelial Keratoplasty.
    Borkar DS, Veldman P, Colby KA, et al. · Cornea · 2017 · Background
    PubMed: PMID 27310885 · NCT03971357 · Fuchs' Endothelial Dystrophy

2016 (1 paper)

  1. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    Lewis RA, Levy B, Ramirez N, et al. · Br J Ophthalmol · 2016 · Derived
    PubMed: PMID 26209587 · NCT02057575 · Glaucoma, Open-Angle

2015 (1 paper)

  1. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy.
    Arbelaez JG, Price MO, Price FW, et al. · Cornea · 2015 · Background
    PubMed: PMID 25299425 · NCT03971357 · Fuchs' Endothelial Dystrophy

2014 (1 paper)

  1. Circadian variation of aqueous humor dynamics in older healthy adults.
    Nau CB, Malihi M, McLaren JW, et al. · Invest Ophthalmol Vis Sci · 2014 · Background
    PubMed: PMID 24243986 · NCT07325240 · Glaucoma, Open-Angle

2012 (1 paper)

  1. Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure.
    Tung JD, Tafreshi A, Weinreb RN, et al. · BMJ Open · 2012 · Background
    PubMed: PMID 22918671 · NCT07325240 · Glaucoma, Open-Angle

2010 (1 paper)

  1. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure.
    Liu JH, Medeiros FA, Slight JR, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20663566 · NCT07325240 · Glaucoma, Open-Angle

2009 (2 papers)

  1. Visual acuity and intraocular pressure after Descemet's stripping endothelial keratoplasty in eyes with and without preexisting glaucoma.
    Vajaranant TS, Price MO, Price FW, et al. · Ophthalmology · 2009 · Background
    PubMed: PMID 19643499 · NCT03248037 · Fuchs' Endothelial Dystrophy
  2. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH, Medeiros FA, Slight JR, et al. · Ophthalmology · 2009 · Background
    PubMed: PMID 19157559 · NCT07325240 · Glaucoma, Open-Angle

2008 (1 paper)

  1. Circadian variation of aqueous dynamics in young healthy adults.
    Sit AJ, Nau CB, McLaren JW, et al. · Invest Ophthalmol Vis Sci · 2008 · Background
    PubMed: PMID 18385065 · NCT07325240 · Glaucoma, Open-Angle

2006 (1 paper)

  1. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.
    Sit AJ, Weinreb RN, Crowston JG, et al. · Am J Ophthalmol · 2006 · Background
    PubMed: PMID 16765686 · NCT07325240 · Glaucoma, Open-Angle

2004 (1 paper)

  1. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH, Kripke DF, Weinreb RN, et al. · Am J Ophthalmol · 2004 · Background
    PubMed: PMID 15364220 · NCT07325240 · Glaucoma, Open-Angle

2002 (1 paper)

  1. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
    Kass MA, Heuer DK, Higginbotham EJ, et al. · Arch Ophthalmol · 2002 · Background
    PubMed: PMID 12049574 · NCT06865144 · Glaucoma, Open-Angle

1992 (1 paper)

  1. Flow of aqueous humor in humans [The Friedenwald Lecture].
    Brubaker RF · Invest Ophthalmol Vis Sci · 1992 · Background
    PubMed: PMID 1748546 · NCT07325240 · Glaucoma, Open-Angle

1980 (1 paper)

  1. Methods for cosinor-rhythmometry.
    Nelson W, Tong YL, Lee JK, et al. · Chronobiologia · 1980 · Background
    PubMed: PMID 548245 · NCT07325240 · Glaucoma, Open-Angle

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).